Drug intelligence / Profile preview

SKL13865

Development stage: Unknown
Lead developer: SK Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SKL13865 is an investigational small molecule being developed by SK Biopharmaceuticals for the treatment of attention deficit hyperactivity disorder (ADHD). It functions as a dual dopamine and norepinephrine reuptake inhibitor (DNRI), a mechanism designed to increase the synaptic concentrations of these neurotransmitters in the central nervous system to improve focus and reduce hyperactivity. As of early 2024, the compound is in Phase 1 clinical development, where its safety, tolerability, and pharmacokinetic profile are being evaluated in human subjects.

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on SKL13865.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKL13865.

Explore the full profile